BioSpace News Archive

Abbott (NYSE: ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.

Nykode Therapeutics ASA announced an expanded clinical development plan for VB10.16, the Company’s wholly-owned cancer vaccine, for the treatment of HPV16-positive cancers with high unmet need.

REGiMMUNE Limited announced the positive results of their Phase 2b clinical trial for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation at the 2022 American Society of Hematology Annual Meeting.

Sosei Group Corporation announces its President & CEO Chris Cargill will present at the 41st Annual J.P. Morgan Healthcare Conference.

Verona Pharma plc, announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

Mainz Biomed NV announced the first patient has been enrolled in eAArly DETECT, Mainz’s U.S. extension of ColoFuture, its European feasibility study evaluating the integration of a portfolio of novel gene expression biomarkers into ColoAlert.

Mabwell Bioscience announced the company has entered into an licensing agreement with Binnopharm Group, for 9MW0113, 9MW0321 and 9MW0311, its Adalimumab and Denosumab biosimilars, under which Binnopharm Group will have exclusive rights to develop, register, manufacture and market the drugs with a status of local product in Russia and Eurasian Economic Union countries.9MW0113 is a biosimilar of Humira®, Junmaikang was approved in China for 8 indications

Mestag Therapeutics, an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory disease, announced the appointment of Prof. Ton Logtenberg as Chair.

As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology platforms for its therapeutic Herpes simplex virus type 2, HSV-2, vaccine candidates.

Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXI N (SIM 0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute of Materia Medica (the “SIMM”) and Wuhan Institute of Virology (the “WIV”), Chinese Academy of Sciences (the “CAS”), has achieved a major clinical milestone.